This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ALPCHANGE | |
|---|---|
| Name | ALPCHANGE |
ALPCHANGE ALPCHANGE is a term used to denote alterations in alkaline phosphatase activity observed across clinical, biochemical, and population studies. It intersects with findings from World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, European Medicines Agency, and major academic centers such as Johns Hopkins Hospital, Mayo Clinic, and Massachusetts General Hospital. Reports on ALPCHANGE appear in literature associated with journals like The Lancet, New England Journal of Medicine, Nature Medicine, and BMJ.
ALPCHANGE refers to deviations from reference ranges of alkaline phosphatase described in guidelines from American Association for Clinical Chemistry, Royal College of Pathologists, and regulatory frameworks like Clinical Laboratory Improvement Amendments. The concept spans presentations cited in case series from Cleveland Clinic, cohort analyses from Framingham Heart Study, and trials registered with European Clinical Trials Database and ClinicalTrials.gov. Clinical vignettes feature patients from settings such as Johns Hopkins Hospital, Mount Sinai Hospital (New York City), and UCLA Medical Center.
Mechanistic discussions link ALPCHANGE to processes studied at institutions like Harvard Medical School, Stanford University School of Medicine, and University of Oxford. Pathways involve hepatobiliary factors reported in work from Addenbrooke's Hospital, bone remodeling patterns examined by researchers at Karolinska Institutet and McGill University Health Centre, and placental isoenzyme dynamics documented in obstetric units including Guy's Hospital and St Thomas' Hospital. Molecular studies cite signaling components explored at Broad Institute, Sanger Institute, and Max Planck Institute for Molecular Genetics.
Assessment methods derive from standards set by International Federation of Clinical Chemistry and Laboratory Medicine and use assays developed by companies like Roche, Siemens Healthineers, and Abbott Laboratories. Reference interval work cites population baselines from NHANES (National Health and Nutrition Examination Survey), pediatric panels from Children's Hospital of Philadelphia, and geriatric analyses from Johns Hopkins Geriatrics. Quality control frameworks reference College of American Pathologists proficiency testing and accreditation by Joint Commission.
Altered ALPCHANGE values are clinically interpreted in contexts similar to case series from Royal Free Hospital, transplant cohorts at University Hospital Heidelberg, and oncology units such as MD Anderson Cancer Center. Differential considerations include hepatobiliary disorders highlighted in guidelines by American College of Gastroenterology and skeletal pathology discussed in consensus statements from American Academy of Orthopaedic Surgeons. Prognostic implications are reported in outcome studies from St Bartholomew's Hospital, Toronto General Hospital, and Karolinska University Hospital.
Population-level patterns of ALPCHANGE are described using surveillance from World Health Organization, national surveys like NHANES (National Health and Nutrition Examination Survey), and registries including UK Biobank and Danish National Patient Registry. Risk factor analyses reference cohorts such as Nurses' Health Study, Health Professionals Follow-up Study, and Whitehall Study, with demographic correlates reported by Office for National Statistics and Statistics Canada.
Management approaches align with therapeutic protocols from European Association for the Study of the Liver, interventional strategies trialed at Cleveland Clinic and Mayo Clinic, and pharmacologic guidance from Food and Drug Administration approvals. Multidisciplinary care pathways are modeled on programs at Mount Sinai Hospital (New York City), Barnes-Jewish Hospital, and Royal Infirmary of Edinburgh, while educational resources mirror materials from American Medical Association and British Medical Journal clinical reviews.
Ongoing research into ALPCHANGE occurs within networks like Human Genome Project follow-up centers, collaborative consortia at International HapMap Project sites, and trials funded by National Institutes of Health and Wellcome Trust. Emerging topics include omics integration from European Bioinformatics Institute, biomarker validation studies in Journal of Clinical Investigation-affiliated groups, and implementation research linked to NIHR (National Institute for Health Research). Experimental therapeutics are being investigated in phase trials at Vanderbilt University Medical Center, University of California, San Francisco, and Kings College Hospital.
Category:Biomarkers